Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 1

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
, 2025 and December 31, 2024, respectively 
     1,052  
     986 
  
    Share subscription receivable 
     (695,825) 
     — 
  
    Additional paid-in capital 
     —  
     34,014 
  
    Accumulated deficit 
     (6,456,942) 
     (279,845)
  
    Total Shareholders’ Deficit 
     (7,151,715) 
     (244,845)
  
    TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT 
    $235,205,692  
    $550,824 

The accompanying notes are an integral part of
the unaudited financial statements.

1

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENTS OF OPERATIONS

(UNAUDITED) 

    Three Months Ended June 30, 2025

    Six Months Ended June 30, 2025

    For the 
Period from 
May 23,
 2024
 (inception) through June 30, 2024

    General and administrative costs
     
    $
    131,919

    $
    462,844

    $
    54,931

    Loss from operations

    (131,919
    )

    (462,844
    )

    (54,931
    )

    OTHER INCOME

    Interest earned on cash and investments held in Trust Account

    2,420,498

    4,005,966

    —

    Total other income

    2,420,498

    4,005,966

    —

    NET INCOME (LOSS)
     
    $
    2,288,579

    $
    3,543,122

    $
    (54,931
    )

    Weighted average redeemable ordinary shares outstanding – basic and diluted

    23,000,000

    19,110,497

    —

    Basic and diluted net income (loss) per redeemable ordinary share
     
    $
    0.07

    $
    0.12

    $
    —

    Weighted average non-redeemable ordinary shares outstanding (1)(2)

    10,517,143

    10,067,451

    8,571,429